News

The Pharma Letter5h
Yeztugo holds potential to address key unmet needs for PrEP usage
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...
A University of Utah doctor’s research led to a major HIV drug. He worries federal cuts will stop people from getting it.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
The Observer8h
Ugandan firm to manufacture $28,000 HIV drug for just $50
In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...
FDA approves HIV drug based on University of Utah biochemist’s findings
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.
Safeguarding the windows to the soul
Stay informed on health matters with Zubeda Hamid's newsletter covering cataract surgeries, maternal health, and medical ...
Wall Street Journal23h
Gilead’s HIV Breakthrough - WSJ - The Wall Street Journal
Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.
San Francisco Examiner3h
Coverage questions mute enthusiasm for HIV drug approval
Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...
pharmaphorum14h
Gilead’s CD47 woes continue, this time in solid tumours
Gilead Sciences has paused enrolment in clinical trials of its CD47 drug magrolimab in solid tumours, a week after dropping it for blood cancers.